These signals can cause anti-tumor immune cells to stop functioning or increase the development of immunosuppressive receptors (e.g., PD-1, TIM-3, and LAG-3) on the surface of effector cells, thus boosting immunotherapy resistance67,68. Here, PDCD1 is linked to neoplasm.